Andrew Ashe is the president, chief operating officer and general counsel at Verve Therapeutics. He is an accomplished biotech executive with over 20 years of experience in operations and legal management. Prior to joining Verve, Andrew served as a senior executive and general counsel for several biotechnology companies, most notably at Dyax Corp. where he managed legal, operations and administrative functions during a period of growth in which market capitalization increased from $180 million to $6 billion. He also established more than 75 revenue-generating collaborations with biotech and pharma companies in the United States, Europe, India, Australia, and Japan. Andrew remained with Dyax until it was acquired by Shire in 2016, after which he served as a consultant and as an executive at Applied Genetic Technologies Corporation. Previously, Andrew was a member of the business law practices at Prince Lobel Tye LLP and Nutter, McClennen & Fish LLP. Earlier in his career, he served as a trading specialist and senior analyst at the American and New York Stock Exchanges. 

Andrew holds a B.A. in Finance from the Isenberg School of Management at the University of Massachusetts and a J.D. from the George Washington University School of Law.